X
No Ads. No Trackers. No Kidding! (Learn More)
Loading...
Thumbnail
An analyst unceremoniously chops his recommendation on the stock. [Read More]
Thumbnail
The company gets a regulatory nod that will put $25 million in its pocket. [Read More]
Thumbnail
But peeking under the hood, the month-over-month comparisons aren't so impressive. [Read More]
Thumbnail
A version rolling out next year will apparently contain a blood sugar monitor. [Read More]
Thumbnail
Research published in a medical journal provides enormous hope for the company's pipeline Alzheimer's drug. [Read More]
Thumbnail
The company got the green light to launch phase 2 testing in the U.K. for its experimental COVID-19 treatment. [Read More]
Thumbnail
The biotech is bulking up with a new acquisition. [Read More]
Thumbnail
The move will occur at the end of this month. [Read More]
Thumbnail
Uber has a nearly 14% stake in its Asian peer. [Read More]
The deal is aimed at strengthening the company's NVIDIA DRIVE system. [Read More]
WallStreetBets strikes again! [Read More]
The company will bring a lower dose of an important pipeline drug into a phase 2 clinical trial. [Read More]
The popular corporate-messaging software will be integrated into most, if not all, of the sprawling-company's offerings. [Read More]
The popular corporate-messaging software will be integrated into most, if not all, of the sprawling-company's offerings. [Read More]
The Waymo Via system will be put through its paces on the Houston-to-Fort Worth run. [Read More]
The company won't be getting emergency use authorization for Covaxin after all. [Read More]
No, the company didn't suffer another global outage. [Read More]
The patients all received both doses of either the Moderna or Pfizer/BioNTech vaccine. [Read More]
The cannabis executive reveals a few ways his under-the-radar company is trying to succeed in an immature business that is rarely profitable. [Read More]
Loading...
Save As
Preview
Preview